BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/25/2020 2:44:05 PM | Browse: 1106 | Download: 2096
 |
Received |
|
2020-09-11 17:53 |
|
Peer-Review Started |
|
2020-09-11 17:54 |
|
First Decision by Editorial Office Director |
|
2020-09-29 23:26 |
|
Return for Revision |
|
2020-09-30 06:55 |
|
Revised |
|
2020-10-01 09:21 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-10-29 11:00 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-11-02 04:15 |
|
Articles in Press |
|
2020-11-02 04:15 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-11-10 09:00 |
|
Publish the Manuscript Online |
|
2020-11-25 14:44 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Alessandra Mangia, Giovanni Cenderello, Gabriella Verucchi, Alessia Ciancio, Andrea Fontana, Valeria Piazzolla, Nicola Minerva, Maria Maddalena Squillante and Massimiliano Copetti |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Alessandra Mangia, MD, N/A, N/A, N/A, Liver Unit, Department of Medical Sciences, Fondazione IRCCS “Casa Sollievo della Sofferenza”, viale Cappuccini,1, San Giovanni Rotondo 71013, Italy. a.mangia@tin.it |
| Key Words |
Hepatitis C virus; Hepatitis B virus; Cirrhosis; COVID-19; Sofosbuvir; Velpatasvir |
| Core Tip |
This ongoing study aims to investigate the potential reciprocal influence of coronavirus disease 2019 (COVID-19) and pre-existing cirrhosis. To date, it has included 332 patients with COVID-19 admitted to three Italian hospitals during the current pandemic, as well as two large cohorts of hepatitis C virus (HCV) patients from real-world antiviral treatment (pangenotypic sofosbuvir/velpatasvir combination) studies. Despite the limited COVID-19 sample size, cirrhosis was found to be associated with higher mortality, with the majority of deaths related to cirrhosis of metabolic origin. The very low prevalence of COVID-19 in the HCV cohorts supports a possible protective role of HCV antibodies. |
| Publish Date |
2020-11-25 14:44 |
| Citation |
Mangia A, Cenderello G, Verucchi G, Ciancio A, Fontana A, Piazzolla V, Minerva N, Squillante MM, Copetti M. Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis? World J Clin Cases 2020; 8(22): 5831-5834 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i22/5831.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i22.5831 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
